We are live on ! Find out more
NNNN icon

Anbio Biotechnology

5 hedge funds and large institutions have $937K invested in Anbio Biotechnology in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

67% more funds holding

Funds holding: 3 → 5 (+2)

0.08% less ownership

Funds ownership: 0.15% → 0.07% (-0.08%)

80% less capital inflows, than outflows

Capital inflows: $64.9K | Capital outflows: $325K

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NNNN Hedge Fund Activity: Q2 2025 in Review

5 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Anbio Biotechnology (NNNN) for Q2 2025, worth a combined $937K — up 89% from $496K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NNNN positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $47.4K. The largest seller was Marshall Wace, exiting entirely with an estimated $325K sold.

  • 5 institutional investors held Anbio Biotechnology (NNNN) as of Q2 2025, up from 3 in Q1 2025.
  • Funds reported $937K of Anbio Biotechnology stock for Q2 2025, up 89% quarter-over-quarter.
  • 3 funds opened new Anbio Biotechnology positions in Q2 2025 and 1 closed out, a net change of +2 holders.
  • The largest Anbio Biotechnology buyer in Q2 2025 was UBS Group, an estimated $47.4K added.
  • The largest Anbio Biotechnology seller in Q2 2025 was Marshall Wace, an estimated $325K sold.

Based on aggregated 13F filings for Q2 2025.